TJ

Timothy J. Barberich

North America, Massachusetts, United States, Cambridge

Description

Tim Barberich is the Director at Newcastle Holdings and was a Chairman and CEO of Sunovion Pharmaceuticals. Tim attended Rutgers University ...

Investor Profile

Timothy J. Barberich has backed more than 2 startups, with 0 new investments in the last 12 months alone. The firm has led 0 rounds, about 0% of its total and boasts 1 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series Unknown, Series A rounds (top funding stages).
  • Majority of deals are located in United States.
  • Strong thematic focus on Biotechnology, Clinical Trials, Health Care.

Stage Focus

  • Series Unknown (50%)
  • Series A (50%)

Country Focus

  • United States (100%)

Industry Focus

  • Biotechnology
  • Clinical Trials
  • Health Care
  • Neuroscience
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Timothy J. Barberich frequently co-invest with?

Novartis Venture Fund
Europe, Basel-Stadt, Switzerland, Basel
Co-Investments: 2
Tekla Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 2
Venture Investors
North America, Wisconsin, United States, Madison
Co-Investments: 1
State of Wisconsin Investment Board
North America, Wisconsin, United States, Madison
Co-Investments: 2
GBS Ventures
Oceania, Victoria, Australia, Melbourne
Co-Investments: 2
HH
North America, Massachusetts, United States, Boston
Co-Investments: 2

What are some of recent deals done by Timothy J. Barberich?

Neurovance

Cambridge, Massachusetts, United States

Neurovance is a clinical-stage neuroscience company that discovered and developed centanafadine (CTN) to help adults and children with ADHD.

BiotechnologyClinical TrialsHealth CareNeuroscience
Series AApr 3, 2014
Amount Raised: $6,300,000
Neurovance

Cambridge, Massachusetts, United States

Neurovance is a clinical-stage neuroscience company that discovered and developed centanafadine (CTN) to help adults and children with ADHD.

BiotechnologyClinical TrialsHealth CareNeuroscience
Series UnknownOct 18, 2012
Amount Raised: $7,000,000

Find More Investors Like Timothy J. Barberich

Discover similar investors in our database and build your perfect investor list.

Need help with your fundraising strategy?Read our fundraising guides

Timothy J. Barberich | Pipeseed